Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,679 | 95 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $335.90 | 22 | $0 (2023) |
| GlaxoSmithKline, LLC. | $333.03 | 22 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $298.61 | 16 | $0 (2022) |
| ABIOMED | $147.02 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $145.17 | 10 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $57.54 | 3 | $0 (2023) |
| PFIZER INC. | $54.73 | 4 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.86 | 2 | $0 (2023) |
| Baxter Healthcare | $42.68 | 1 | $0 (2021) |
| Grifols USA, LLC | $42.63 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $363.96 | 14 | ABIOMED ($147.02) |
| 2022 | $518.78 | 32 | GlaxoSmithKline, LLC. ($134.75) |
| 2021 | $697.75 | 42 | GlaxoSmithKline, LLC. ($153.41) |
| 2020 | $98.27 | 7 | GlaxoSmithKline, LLC. ($29.05) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Respiratory | ||||||
| 05/19/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Respiratory | ||||||
| 05/12/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: Respiratory | ||||||
| 04/21/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Cardio-pulmonary | ||||||
| 04/06/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/23/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $147.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Cardio-pulmonary | ||||||
| 02/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: IMMUNOLOGY | ||||||
| 02/02/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/19/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: IMMUNOLOGY | ||||||
| 01/19/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2022 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/10/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $29.33 | General |
| Category: RESPIRATORY | ||||||
| 10/27/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/29/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2022 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Hematology | ||||||
| 08/19/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $13.64 | General |
| 08/12/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: IMMUNOLOGY | ||||||
| 07/29/2022 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/28/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 133 | 256 | $88,983 | $36,994 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 76 | 171 | $72,846 | $28,268 | 38.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 56 | $8,904 | $5,236 | 58.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 17 | $5,253 | $2,317 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $1,980 | $1,173 | 59.2% |
About Dr. Najam Siddiqui, DO
Dr. Najam Siddiqui, DO is a Critical Care Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2017. The National Provider Identifier (NPI) number assigned to this provider is 1598297194.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Najam Siddiqui, DO has received a total of $1,679 in payments from pharmaceutical and medical device companies, with $363.96 received in 2023. These payments were reported across 95 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($1,679).
As a Medicare-enrolled provider, Siddiqui has provided services to 133 Medicare beneficiaries, totaling 256 services with total Medicare billing of $36,994. Data is available for 1 year (2023–2023), covering 4 distinct procedure/service records.
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Dallas, TX
- Active Since 04/01/2017
- Last Updated 01/30/2024
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1598297194
Products in Payments
- NUCALA (Biological) $305.01
- LOKELMA (Drug) $280.27
- OFEV (Drug) $161.30
- Impella (Device) $147.02
- STIOLTO RESPIMAT (Drug) $137.31
- ELIQUIS (Drug) $90.16
- DIFICID (Drug) $67.72
- ZERBAXA (Drug) $62.98
- Adempas (Drug) $57.54
- FASENRA (Biological) $55.63
- GLASSIA (Biological) $47.86
- STARLING SYSTEM (Device) $42.68
- Prolastin-C Liquid (Biological) $42.63
- Arikayce (Drug) $40.51
- Fetroja (Drug) $34.26
- TRELEGY ELLIPTA (Drug) $28.02
- Andexxa (Drug) $22.31
- Veklury (Drug) $14.86
- RECARBRIO (Drug) $14.47
- Xolair (Biological) $12.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Dallas
Dr. Yolanda Mageto, Md, MD
Critical Care Medicine — Payments: $248,495
Sonja Bartolome, M.d, M.D
Critical Care Medicine — Payments: $194,111
Corey Kershaw, Md, MD
Critical Care Medicine — Payments: $116,660
Dr. Jagadeshwar Reddy, M.d, M.D
Critical Care Medicine — Payments: $10,977
Mr. Humayun Anjum, M.d, M.D
Critical Care Medicine — Payments: $10,184
Todd Grazia, Md, MD
Critical Care Medicine — Payments: $8,074